Cue Biopharma (CUE) Operating Margin (2018 - 2025)

Cue Biopharma has disclosed Operating Margin across 8 years of filings, most recently posting 242.62% for Q4 2025.

• Operating Margin for Q4 2025 came in at 242.62%, down 123746.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 36.47% (up 5548.0% YoY), and the FY2025 annual result was 19.96%, up 7201.0% from the prior year.
• Operating Margin came in at 242.62% for Q4 2025 at Cue Biopharma, up from 353.42% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 1480.08% in Q4 2024 to a low of 50346.15% in Q2 2022.
• The 5-year median for Operating Margin is 640.78% (2023), against an average of 4616.6%.
• Across the five-year window, Operating Margin plunged 4996999 bps in 2022 and surged 4936808 bps in 2023, its largest moves.
• Cue Biopharma's Operating Margin stood at 95.62% in 2021, then slumped by 10196 bps to 9845.03% in 2022, then soared by 92 bps to 759.58% in 2023, then surged by 295 bps to 1480.08% in 2024, then plunged by 84 bps to 242.62% in 2025.
• The last three Operating Margin figures came in at 242.62% (Q4 2025), 353.42% (Q3 2025), and 292.32% (Q2 2025), per Business Quant data.